AI Drug Discovery: News & Recent Developments
Oct 31, 2024 Accenture and 1910 Genetics Partner to Accelerate AI-Driven Drug Discovery. (Source) Servier and Aitia Partner to Advance Glioma Drug Discovery with AI and Digital Twins. (Source) Oct 30, 2024 Archon Biosciences debuts with $20M seed funding to pioneer “antibody cages,” a novel class of therapeutics. (Source) Insilico Medicine and Sanofi’s AI-driven drug […]
Cell Therapy: News & Recent Developments
Oct 30, 2024 Galapagos reports strong Q3 progress, including advancing CAR-T programs to clinical trials. Cell therapy, non-Hodgkin lymphoma, cancer (Source) Oct 24, 2024 Coeptis and Deverra Collaborate to Combat Viral Infections and Strengthen Pandemic Preparedness with Allogeneic NK Cell Therapy. (Source) Lyell Immunopharma to Acquire ImmPACT Bio, Prioritizing Next-Gen CAR T-cell Therapies. (Source) Oct […]
CRISPR Gene Editing: News & Recent Developments
Oct 24, 2024 Tessera Releases Promising Preclinical Data for Its In Vivo Gene Editing Technology, Showcasing Potential Treatments for Alpha-1 Antitrypsin Deficiency and Sickle Cell Disease. (Source) Intellia Announces Positive Data from Phase 2 Trial of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema. (Source) Precision BioSciences secures approval for its […]
Cell and Gene Therapy (CGT): News & Recent Developments
Oct 17, 2024 OmniaBio Opens New Commercial Manufacturing Facility in Canada for Cell and Gene Therapies. (Source) Oct 10, 2024 Aenitis Raises Strategic Funding to Revolutionize Bioproduction with Sole-In-Class Acoustofluidic Technology. (Source) Sept 26, 2024 Mirai Bio, a new venture from Flagship Pioneering, aims to address drug delivery issues in genetic therapies. Cell and gene […]
Gene Therapy: News & Recent Developments
Oct 31, 2024 Spur Therapeutics announces positive preclinical results for SBT101, its gene therapy candidate designed to treat Adrenomyeloneuropathy (AMN). (Source) Oct 30, 2024 Lexeo Therapeutics Reports Positive Interim Data for LX1001, a Novel Gene Therapy Targeting APOE4-Associated Alzheimer’s Disease, at CTAD. Gene therapy, Alzheimer’s disease, AAV (Source) Oct 29, 2024 Abeona Therapeutics Resubmits Biologics […]
GLP-1 Drugs: News & Recent Developments
Oct 28, 2024 Eli Lilly’s GLP-1 drug Mounjaro receives Hong Kong approval for treating obesity and associated health problems like type 2 diabetes. (Source) Ironwood Pharmaceuticals highlights positive Phase 3 data for its GLP-2 peptide, apraglutide, in treating short bowel syndrome, aiming to bolster investor confidence. (Source) Oct 24, 2024 Novo Nordisk’s semaglutide, a GLP-1 […]
Bispecific Antibody: News & Recent Developments
Oct 31, 2024 Roche’s bispecific antibody, trontinemab, demonstrates significant potential in Alzheimer’s treatment, rapidly reducing amyloid plaques in early-stage trials, despite a reported patient death. (Source) Oct 30, 2024 The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Pfizer’s bispecific T-cell engager, Elrixfio, as a treatment for multiple myeloma. […]
mRNA Vaccine: News & Recent Developments
Oct 16, 2024 GSK files lawsuit against Moderna alleging unauthorized use of their COVID-19 mRNA vaccine patents. (Source) Oct 03, 2024 New Scientific Study: A multivalent mRNA-LNP vaccine offers protection against Clostridioides difficile infection. (Source) Aug 16, 2024 Pfizer and BioNTech‘s combined COVID-19 and influenza vaccine falls short of its primary goal in Phase 3 […]
Vaccine: News & Recent Developments
Oct 29, 2024 Vaxinano Secures €6 Million ($6.5M) Investment to Bring Nasal Vaccines Closer to Clinical Testing. (Source) Clover’s SCB-1019 RSV vaccine shows promising results in Phase 1 clinical trials, demonstrating superiority over GSK’s Arexvy. (Source) Oct 28, 2024 Vaxxas Partners with NIH to Develop Needle-Free RSV Vaccine. (Source) Oct 24, 2024 GSK reports positive […]
Biomarkers in Precision Oncology / Cancer Biomarkers
Biomarkers in Precision Oncology / Cancer Biomarkers: The landscape of cancer research has witnessed a paradigm shift, moving towards a more personalized approach. This transformation is largely driven by the identification and validation of key biomarkers, specific molecules that can serve as indicators of disease progression or potential treatment targets. As highlighted in the accompanying […]